•Journal•ISSN: 1073-2748
Cancer Control
SAGE Publishing
About: Cancer Control is an academic journal published by SAGE Publishing. The journal publishes majorly in the area(s): Cancer & Medicine. It has an ISSN identifier of 1073-2748. It is also open access. Over the lifetime, 1843 publications have been published receiving 42324 citations.
Topics: Cancer, Medicine, Breast cancer, Population, Internal medicine
Papers published on a yearly basis
Papers
More filters
TL;DR: Third-generation P-gp inhibitors have shown promise in clinical trials and may establish the true therapeutic potential of P- gp-mediated MDR reversal, and pharmacokinetic studies to date have shown no appreciable impact on cytochrome P450 3A4 drug metabolism and no clinically significant drug interactions with common chemotherapy agents.
Abstract: BackgroundMultidrug resistance (MDR) is a significant obstacle to providing effective chemotherapy to many patients. Multifactorial in etiology, classic MDR is associated with the overexpression of...
846 citations
TL;DR: Given the rising prevalence of several common HCC and ICC risk factors in the western world, the best opportunities for improving the care of these patients are either through the prevention of modifiable risk factors that are associated with the development of chronic liver disease or the identification of at risk patients.
Abstract: Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most frequently occurring types of primary liver cancer and together are among the most common incident cancers worldwide. There are a number of modifiable and nonmodifiable HCC and ICC risk factors that have been reported. A review of the existing literature the epidemiology and risk factors for HCC and ICC was performed. There are a number of major infectious, lifestyle, metabolic, and heritable risk factors for both HCC and ICC. Some of these risk factors are either potentially preventable (eg, alcohol and tobacco use) or are currently treatable (eg hepatitis infection). In most cases, the molecular pathway or mechanism by which these etiologic factors cause primary liver cancer has not been well delineated. However, in nearly all cases, it is believed that a given risk factor causes liver injury and inflammation which results in chronic liver disease. Given the rising prevalence of several common HCC and ICC risk factors in the western world, the best opportunities for improving the care of these patients are either through the prevention of modifiable risk factors that are associated with the development of chronic liver disease or the identification of at risk patients, ensuring they are appropriately screened for the development of primary liver cancer, and initiating treatment early.
376 citations
TL;DR: The role of CGA in the identification and management of frail elderly patients and a more accurate evaluation of prognostic indicators that includes CGA parameters could lead to a higher number of older patients being included in clinical cancer trials and being treated effectively in practice.
Abstract: Comprehensive geriatric assessment is a multidimensional, often interdisciplinary diagnostic process designed to define an elderly individual’s medical, psychosocial, and functional capabilities and problems to arrive at an overall plan for therapy and long-term follow-up. While comprehensive clinical assessment methodologies have benefited nonelderly groups of patients as well, multidimensional assessment has asssumed a key role in geriatric care because the delicate complexity of the typical frail elderly patient demands multidimensional diagnosis to attain both a reasonable understanding of the patient’s problems and a prudent plan of treatment.
335 citations
TL;DR: Staging bias may affect the overall low survival of early-stage NSCLC, but true stage-specific survival may improve with newer imaging modalities, and methods for further improvements in posttreatment survival in this group are discussed.
Abstract: Background: The appropriate staging and treatment of patients with stage I and II non‐small-cell lung cancer (NSCLC) are important in that the potential for a lost curative opportunity in this population is greater than for those presenting with advanced NSCLC. Methods: Treatment options — surgery, radiation therapy, and chemotherapy — for stage I and II NSCLC are reviewed, and the impact of newer staging modalities on patient survival is discussed, including altering both the lead-time and clinicopathologic stage biases that exist in the diagnosis and treatment of NSCLC. Some predictions are also made regarding how that standard may change for clinicians in the near future, and methods for further improvements in posttreatment survival in this group are discussed. Results: Whenever possible, patients with early-stage NSCLC should be treated with surgical resection. Patients for whom resection is not an option may benefit from radiation as definitive therapy. Positive results with neoadjuvant chemotherapy have led to an ongoing randomized trial (Intergroup S9900) to compare surgery alone to neoadjuvant chemotherapy plus surgery. Conclusions: Staging bias may affect the overall low survival of early-stage NSCLC. However, true stage-specific survival may improve with newer imaging modalities. Future advances, including closed transthoracic radiation, thermal ablative therapy techniques, and gene therapy, may supplant the need to surgically resect these tumors to achieve local control.
332 citations
TL;DR: Benign SFTP has a high cure rate and an 8% local recurrence rate that is usually amenable to curative re-excision, and adjuvant therapy remains controversial in SFTP.
Abstract: BackgroundThe solitary fibrous tumor of the pleura (SFTP) is a rare primary tumor arising from mesenchymal cells in the areolar tissue subjacent to the mesothelial-lined pleura. Only about 800 case...
306 citations